122 related articles for article (PubMed ID: 2138080)
1. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.
Pearce RK; Seeman P; Jellinger K; Tourtellotte WW
Eur Neurol; 1990; 30 Suppl 1():9-14. PubMed ID: 2138080
[TBL] [Abstract][Full Text] [Related]
2. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
[TBL] [Abstract][Full Text] [Related]
3. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
4. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
Guttman M; Seeman P
J Neural Transm; 1985; 64(2):93-103. PubMed ID: 2934514
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
Guttman M; Seeman P; Reynolds GP; Riederer P; Jellinger K; Tourtellotte WW
Ann Neurol; 1986 May; 19(5):487-92. PubMed ID: 2940960
[TBL] [Abstract][Full Text] [Related]
6. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
7. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors.
Churchyard A; Donnan GA; Hughes A; Howells DW; Woodhouse D; Wong JY; Kalnins RM; Mendelsohn FA; Paxinos G
Ann Neurol; 1993 Aug; 34(2):219-26. PubMed ID: 8338346
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease.
Robertson HA
Trends Neurosci; 1992 Jun; 15(6):201-6. PubMed ID: 1378662
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.
Seeman P; Guan HC; Nobrega J; Jiwa D; Markstein R; Balk JH; Picetti R; Borrelli E; Van Tol HH
Synapse; 1997 Feb; 25(2):137-46. PubMed ID: 9021894
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
Robertson HA
Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
[TBL] [Abstract][Full Text] [Related]
11. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type.
Allard PO; Rinne J; Marcusson JO
Brain Res; 1994 Feb; 637(1-2):262-6. PubMed ID: 8180805
[TBL] [Abstract][Full Text] [Related]
12. Dopamine receptors in Parkinson's disease.
Hassan MN; Thakar JH
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
Barbanti P; Fabbrini G; Ricci A; Cerbo R; Bronzetti E; Caronti B; Calderaro C; Felici L; Stocchi F; Meco G; Amenta F; Lenzi GL
Mov Disord; 1999 Sep; 14(5):764-71. PubMed ID: 10495037
[TBL] [Abstract][Full Text] [Related]
14. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.
Pimoule C; Schoemaker H; Reynolds GP; Langer SZ
Eur J Pharmacol; 1985 Aug; 114(2):235-7. PubMed ID: 2864273
[No Abstract] [Full Text] [Related]
15. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
16. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
Joyce JN; Lexow N; Bird E; Winokur A
Synapse; 1988; 2(5):546-57. PubMed ID: 2973147
[TBL] [Abstract][Full Text] [Related]
17. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D4 receptors elevated in schizophrenia.
Seeman P; Guan HC; Van Tol HH
Nature; 1993 Sep; 365(6445):441-5. PubMed ID: 8413587
[TBL] [Abstract][Full Text] [Related]
19. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ
Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
